Clinical trial
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
NCT03499808 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 6, 2018
- Completion date
- September 19, 2023
- Enrollment
- 43 (actual)
- Sites
- 345
Conditions
As the registry lists them; a condition with its own page is linked.
amorphous, eosinophilic, and acellular deposit, constipation, diarrhea, early satiety, gastrointestinal hemorrhage, hepatomegaly, lymphadenopathy, macroglossia, nausea, primary systemic amyloidosis, purpura, recurrent primary amyloidosis, refractory primary amyloidosis